This week, 8 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

This week, TESARO, Inc.’s (TSRO) ratings are up from a B last week to a A. TESARO, Inc. develops and commercializes cancer therapeutics and supportive care products. The company also gets A’s in earnings surprise and earnings momentum. For more information, get Portfolio Grader’s complete analysis of TSRO stock.

This week, Coherus BioSciences, Inc. (CHRS) pushes up from a C to a B rating. Coherus BioSciences, Inc. focuses on developing and commercializing biosimilar products worldwide. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CHRS stock.

The rating of Flexion Therapeutics, Inc. (FLXN) moves up this week, rising from a C to a B. For more information, get Portfolio Grader’s complete analysis of FLXN stock.

XBiotech, Inc. (XBIT) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of XBIT stock.

CytomX Therapeutics, Inc. (CTMX) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of CTMX stock.

Abeona Therapeutics, Inc. (ABEO) gets a higher grade this week, advancing from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of ABEO stock.

Nymox Pharmaceutical Corp (NYMX) is seeing ratings go up from a C last week to a B this week. Nymox Pharmaceutical Corp is engaged in therapeutics in development for enlarged prostate, E. coli, Alzheimer’s disease and other indications and diagnostics for tobacco exposure, and other conditions. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of NYMX stock.

Venaxis, Inc. (APPY) boosts its rating from a C to a B this week. Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. For more information, get Portfolio Grader’s complete analysis of APPY stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.